Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss. (New ...

He said the deal would reduce the price that Caremark’s employer clients paid for obesity drugs by 10 to 15 percent compared with the previous year. “CVS Caremark was able to do what P.B.M.s ...

Lilly CEO Dave Ricks said most customers affected by CVS's move would be smaller employers that do not tend to cover obesity drugs. Still, "it seems like the wrong idea to reduce choice," he said ...

CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1 ...

CVS Health on Thursday said it will ... Wegovy on its formularies — or lists of covered drugs — making it the preferred GLP-1 drug for obesity. The move is part of a new partnership between ...